Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort

Published:2024-01 Issue: Volume:59 Page:50-54
ISSN:2666-1683
Container-title:European Urology Open Science
language:en
Short-container-title:European Urology Open Science

Author:

Richters Anke^ORCID,Robbrecht Debbie G.J.,Meijer Richard P.,van der Heijden Antoine G.,Kiemeney Lambertus A.L.M.,van den Bosch Joan,Suelmann Britt B.M.,Özdemir Berna C.,Mehra Niven,Aben Katja K.H.

Funder

Merck Pharmaceuticals

AstraZeneca

Astellas Pharma BV

Bristol-Myers Squibb Company

Publisher

Elsevier BV

Subject

Urology

Reference13 articles.

1. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

2. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Powles;Ann Oncol,2022

3. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Engl J Med,2020

4. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study;Richters;Cancer Treat Res Commun,2020

5. Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the ‘Trials Within Cohorts’ study ProBCI;Richters;BMJ Open,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP